Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.celrep.2021.109839 http://scihub22266oqcxt.onion/10.1016/j.celrep.2021.109839 34624208!8481092!34624208     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\34624208.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Cell+Rep 2021 ; 37 (3): 109839 Nephropedia Template TP {{tp|p=34624208|t=2021. Role of miR-2392 in driving SARS-CoV-2 infection |pdf=|usr=}}{{34624208}} gab.com Text Role of miR-2392 in driving SARS-CoV-2 infection JO: Cell Rep http://www.kidney.de/pget.php?&tw=1&pmid=34624208 #FOAvip MicroRNAs (miRNAs) are small non-coding RNAs involved in post-transcriptional gene regulation that have a major impact on many diseases and provide an exciting avenue toward antiviral therapeutics. From patient transcriptomic data, we determined that a circulating miRNA, miR-2392, is directly involved with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) machinery during host infection. Specifically, we show that miR-2392 is key in driving downstream suppression of mitochondrial gene expression, increasing inflammation, glycolysis, and hypoxia, as well as promoting many symptoms associated with coronavirus disease 2019 (COVID-19) infection. We demonstrate that miR-2392 is present in the blood and urine of patients positive for COVID-19 but is not present in patients negative for COVID-19. These findings indicate the potential for developing a minimally invasive COVID-19 detection method. Lastly, using in vitro human and in vivo hamster models, we design a miRNA-based antiviral therapeutic that targets miR-2392, significantly reduces SARS-CoV-2 viability in hamsters, and may potentially inhibit a COVID-19 disease state in humans. Twit Text FOAVip Role of miR-2392 in driving SARS-CoV-2 infection ????Cell Rep http://www.kidney.de/pget.php?&tw=1&pmid=34624208 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34624208 #FOAvip English Wikipedia <ref>{{Cite pmid|34624208}}</ref> Role of miR-2392 in driving SARS-CoV-2 infection #MMPMID34624208 McDonald JT; Enguita FJ; Taylor D; Griffin RJ; Priebe W; Emmett MR; Sajadi MM; Harris AD; Clement J; Dybas JM; Aykin-Burns N; Guarnieri JW; Singh LN; Grabham P; Baylin SB; Yousey A; Pearson AN; Corry PM; Saravia-Butler A; Aunins TR; Sharma S; Nagpal P; Meydan C; Foox J; Mozsary C; Cerqueira B; Zaksas V; Singh U; Wurtele ES; Costes SV; Davanzo GG; Galeano D; Paccanaro A; Meinig SL; Hagan RS; Bowman NM; Wolfgang MC; Altinok S; Sapoval N; Treangen TJ; Moraes-Vieira PM; Vanderburg C; Wallace DC; Schisler JC; Mason CE; Chatterjee A; Meller R; Beheshti A Cell Rep 2021[Oct]; 37 (3): 109839 PMID34624208show ga MicroRNAs (miRNAs) are small non-coding RNAs involved in post-transcriptional gene regulation that have a major impact on many diseases and provide an exciting avenue toward antiviral therapeutics. From patient transcriptomic data, we determined that a circulating miRNA, miR-2392, is directly involved with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) machinery during host infection. Specifically, we show that miR-2392 is key in driving downstream suppression of mitochondrial gene expression, increasing inflammation, glycolysis, and hypoxia, as well as promoting many symptoms associated with coronavirus disease 2019 (COVID-19) infection. We demonstrate that miR-2392 is present in the blood and urine of patients positive for COVID-19 but is not present in patients negative for COVID-19. These findings indicate the potential for developing a minimally invasive COVID-19 detection method. Lastly, using in vitro human and in vivo hamster models, we design a miRNA-based antiviral therapeutic that targets miR-2392, significantly reduces SARS-CoV-2 viability in hamsters, and may potentially inhibit a COVID-19 disease state in humans. |Adult[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |Animals[MESH] |Antiviral Agents/pharmacology[MESH] |Biomarkers/metabolism[MESH] |COVID-19 Drug Treatment[MESH] |COVID-19/*genetics/*immunology[MESH] |Cricetinae[MESH] |Female[MESH] |Ferrets[MESH] |Gene Expression Regulation[MESH] |Glycolysis[MESH] |Healthy Volunteers[MESH] |Humans[MESH] |Hypoxia[MESH] |Inflammation[MESH] |Male[MESH] |Mice[MESH] |MicroRNAs/*genetics[MESH] |Middle Aged[MESH] |Proteomics/methods[MESH] |ROC Curve[MESH] |Rats[MESH]Role of miR-2392 in driving SARS-CoV-2 infection (epmc).pdf DeepDyve Pubget Overpricing